№ files_lp_4_process_2_68908
File format: docx
Character count: 1168
File size: 161 KB
Year:
Not specified
Region / city:
Not specified
Topic:
Medical conditions
Document type:
Educational material
Author:
Not specified
Target audience:
Medical students, healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
Pirassununga, SP, Brazil
Topic:
Veterinary medicine, animal welfare, swine castration
Document Type:
Research article
Institution:
University of Sao Paulo, North Carolina State University, Washington State University, Michigan State University, Iowa State University, University of Missouri
Author:
Laya Kannan Silva Alves, Monique Danielle Pairis-Garcia, Juliana Bonin Ferreira, Victoria Rocha Merenda, Rubia Mitalli Tomacheski, Pedro Henrique Esteves Trindade, Christopher Siepker, Magdiel Lopez-Soriano
Target Audience:
Researchers, veterinary professionals
Period of Study:
Not specified
Approval Date:
Not specified
Date of Revision:
Not specified
Year:
2019
Region / City:
Naas General Hospital
Topic:
Inflammatory Bowel Disease, Biologic Medication
Document Type:
Policy
Author:
Joanna Rea, Inflammatory Bowel Disease Clinical Nurse Specialist
Target Audience:
IBD CNSp, Gastroenterology team, nursing staff administering biologic medication
Approval Date:
14th January 2020
Revision Date:
January 2023
Version Number:
1
Supporting Evidence:
Infliximab, Remicade, Vedolizumab, Adalimumab, Imraldi, Amgevita, Hulio, Golimumab, Ustekinumab
Purpose:
Standardization of pre-screening and management of IBD patients requiring biologic treatment
Scope:
Biologic screening, patient education, IBD CNSp, gastroenterology team, nursing staff
Objective(s):
Ensure best practice for IBD patients on biologics
Outcome(s):
Clarity for staff on safe and evidence-based care for IBD patients on biologics
Governance:
IBD Working Group
Review Group:
Not Applicable
Date of Approval:
14th January 2020
Date of Next Revision:
January 2023
Year:
2015
Region / City:
Zurich, Switzerland
Topic:
Inflammatory bowel disease
Document type:
Journal Article
Organization / Institution:
University Hospital Zurich, University of California Riverside
Author:
Marianne R Spalinger, Declan F McCole, Gerhard Rogler, Michael Scharl
Target audience:
Researchers, medical professionals
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Year:
2010
Region / City:
Global
Document Type:
Medical Research Article
Organization / Institution:
Various Medical Institutions and Study Groups
Author:
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, et al.
Target Audience:
Healthcare professionals, researchers
Period of Action:
2006-2012
Approval Date:
April 15, 2010
Modification Date:
N/A
Note:
Year
Region / City:
Shanghai, China
Topic:
Tumor Immunology, Hepatocarcinogenesis
Document Type:
Research Supplementary Material
Institution:
Third Affiliated Hospital of Second Military Medical University, National Center for Liver Cancer
Author:
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei
Target Audience:
Researchers in Tumor Immunology, Oncology
Context:
A research document providing detailed methods and experimental procedures on hepatocarcinogenesis and tumor immunology based on single-cell analysis and cell culture experiments.
Year:
2025
Month of Revision:
February 2025
Country:
United Kingdom
Healthcare System:
NHS
Service:
Rheumatology Early Inflammatory Arthritis (EIA) Service
Type of Document:
Medical referral form
Target Group:
Patients aged 18 years or above
Referral Priority:
Urgent (3 week wait)
Required Referral Method:
e-RS
Clinical Criteria:
Persistent joint inflammation ≥ 6 weeks in 2 or more joints with specified clinical features
Required Investigations:
FBC, E&C, LFT, ESR, CRP, RhF, ANA, Anti-CCP, X-rays hands/feet if symptomatic
Treatment Pathway Reference:
DMARD therapy within 6 weeks if diagnosis confirmed
Follow-up Sites:
WRH, KTC, ALX
Title of study:
Addressing unmet needs in adult inflammatory bowel disease care
Type of document:
Participant Information Sheet
Study type:
Online survey as part of a Doctor of Philosophy (PhD) Degree
Researcher:
Charlotte Playford
Supervisors:
Stephanie Armstrong; Zahid Asghar; Richard Ngomba; Andrew Rochford
Institution:
University of Lincoln
Collaborating organisation:
National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) East Midlands
Country:
United Kingdom
Target participants:
Healthcare clinicians working within an IBD service in the United Kingdom
Sample size:
Approximately 10 participants
Data collection method:
Online survey and optional follow-up semi-structured interview
Data storage:
University OneDrive and secure university premises
Ethical approval reference:
2024_17184
Funder:
University of Lincoln; NIHR Applied Research Collaboration (ARC) East Midlands
Purpose:
Exploration of clinician perspectives on unmet needs and multidisciplinary care in adult IBD management
Confidentiality:
Anonymous data collection with optional identifiable follow-up consent
Withdrawal policy:
Withdrawal permitted before survey submission
Year:
2024
Region / City:
Rize, Türkiye
Topic:
Geriatric sarcopenia and inflammation
Document Type:
Research article
Institution:
Recep Tayyip Erdoğan University Faculty of Medicine
Authors:
Handan Duman, Damla Tüfekçi
Target Population:
Adults aged ≥80 years
Study Design:
Cross-sectional observational study
Ethics Approval:
Recep Tayyip Erdoğan University Clinical Research Ethics Committee, decision no. 2024/175
Corresponding Author:
Handan Duman, Department of Family Medicine, Recep Tayyip Erdoğan University
Keywords:
Sarcopenia, systemic immune-inflammation index (SII), C-reactive protein/albumin ratio (CAR), very old adults
Methods:
SARC-F questionnaire, handgrip dynamometry, calculation of SII and CAR
Exclusion Criteria:
Age <80 years, active malignancy, acute infection, immunodeficiency, advanced chronic kidney failure, cerebrovascular events, end-stage heart failure, trauma, psychiatric disorders
Running title:
Biomarker ratios for personalized therapeutic decisions
Authors:
Dejana Bajić; Nemanja Todorović; Mladena Lalić Popović; Ljiljana Andrijević
Affiliation:
Department of Biochemistry, Faculty of Medicine, University of Novi Sad; Department of Pharmacy, Faculty of Medicine, University of Novi Sad
Institution:
Institute for Pulmonary Diseases of Vojvodina, Clinic for Intensive Medicine and Vascular Pulmonary Diseases, Department for Intensive Care and Intoxications Level 3
Country:
Serbia
Corresponding author:
Dejana Bajić, MD, PhD
ORCID IDs:
0000-0002-7958-068X; 0000-0002-1519-5643; 0000-0001-8354-3868; 0000-003-0676-7985
Study design:
Retrospective observational clinical study
Study period:
November 2020 – February 2022
Sample size:
133 ICU patients with COVID-19-related sepsis
Primary endpoint:
28-day mortality
Biomarkers analyzed:
Neutrophil-to-lymphocyte ratio (NLR); Fibrinogen-to-albumin ratio (FAR); C-reactive protein-to-albumin ratio (CAR)
Statistical methods:
ROC curve analysis; logistic regression
Ethical approval:
Ethics Committee of the Institute for Pulmonary Diseases of Vojvodina (Protocol Code No. 9-II/3, February 24, 2022); Ethics Committee of the Faculty of Medicine, University of Novi Sad (Protocol Code No. 01-39/190/1)
Conflicts of interest:
None declared
Funding:
No financial support received
Keywords:
biomarkers; COVID-19; inflammation; prognosis
Year:
2023
Region / City:
Not specified
Subject:
Radiology, Musculoskeletal Imaging
Document Type:
Audit Report
Organization / Committee:
ESSR Arthritis Subcommittee, Royal College of Radiologists
Authors:
Dr KS Yung, Dr HM Kwok, Dr NY Pan
Target Audience:
Radiologists, Sonographers, Rheumatologists
Effective Period:
Six months prior to audit or most recent 50 cases
Approval Date:
11 August 2023
Last Reviewed:
1 August 2023
References:
Diekhoff T, Lambert R, Hermann KG (2022); Sudoł-Szopińska I, Jurik AG, Eshed I, et al. (2015); Lambert RG, Bakker PA, van der Heijde D, et al. (2016); Tsoi C, Griffith JF, Lee RKL, Wong PCH, Tam LS (2019); Mandl P, Navarro-Compán V, Terslev L, et al. (2015)
Standards:
MRI sequences for suspected inflammatory sacroiliitis should include coronal oblique T1-weighted and STIR/TIRM, with reporting of active and structural changes, lesion site, number, and location
Year:
2021
Region / City:
Shanghai, China
Topic:
Inflammatory myofibroblastic tumor, Metformin treatment
Document type:
Case report
Organization / Institution:
Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine
Author(s):
Yu Liang, Hong-Xiang Gao, Rui-Cheng Tian, Jing Wang, Yu-Hua Shan, Lei Zhang, Chen-Jie Xie, Jing-Jing Li, Min Xu, Song Gu
Target audience:
Medical professionals, researchers in oncology and pediatrics
Period of validity:
Not applicable
Approval date:
January 16, 2021
Modification date:
Not applicable
Year:
Not specified
Region / city:
Not specified
Topic:
Tumor immunology, treatment methods
Document type:
Scientific article
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, Immunologists
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region/Location:
Not specified
Subject:
Melanoma research
Document type:
Supplementary data tables
Institution:
Research laboratory / academic study
Author:
Not specified
Sample size:
NEVI (14), Primary Malignant Melanoma (23), Metastatic Melanoma (15)
Methods:
Immunohistochemistry for PD-L1, BRAF codon 600 genotyping, inflammatory scoring
Cell lines:
Human melanoma cultured cells
Treatment:
IFN-gamma induction
Data metrics:
%PD-L1 expression, inflammation score, ∆MFI for PD-L1 and MHC I
Context:
Archival melanoma tissue samples and cultured melanoma cell lines analyzed for PD-L1 expression, BRAF mutation status, and immune response markers in experimental study
Year:
2012–2018
Region:
International
Topic:
Inflammatory Bowel Disease, Meta-Analysis
Document Type:
Supplementary Tables
Institution:
Multiple Clinical Research Centers
Authors:
Sebkova, Vadan, De Vos, Molander, Dai, Echarri, Yu, Magro, Pinetun de Chambrun, Prymak, Zhang, Kaymak, Kumar, Munoz-Villafranca
Target Audience:
Clinicians and researchers in gastroenterology
Period Covered:
8 weeks to 2 years follow-up
Data Source:
Published studies included in meta-analyses
Assessment Tool:
Newcastle-Ottawa Scale (NOS)
Statistical Tests:
χ2-test, I2-test
Journal Name:
Asian Research Journal of Gynaecology and Obstetrics
Manuscript Number:
Ms_ARJGO_140463
Type of Article:
ORIGINAL RESEARCH ARTICLE
Authors:
Not specified
Reviewer:
Monisha C, Dr Rela Institute and Medical Center, India
Region:
Nasarawa, Nigeria
Research Focus:
Inflammatory markers and preeclampsia
Ethical Considerations:
Not specified
Language:
English
Target Audience:
Medical and scientific community
Date of Submission:
Not specified
Abstract Quality:
Comprehensive
Scientific Validity:
Confirmed
References:
Sufficient and recent
Note:
Date of Protocol Creation
Topic:
Developmental Disabilities
Document Type:
Protocol
Agency:
Developmental Disabilities Administration (DDA)
Target Audience:
Caregivers, Medical Personnel
Context:
A protocol document detailing emergency procedures, signs, symptoms, and treatments related to bowel-related emergencies for individuals with developmental disabilities, along with guidelines for monitoring and medication.
Note:
Year
Theme:
Healthcare
Document Type:
Healthcare Plan
Note:
Year
Organization:
Aruma
Document type:
Care Plan / Health Management
Target audience:
Aruma staff, treating health professionals
Participant details:
Name, Date of birth, Preferred name, Aruma ID
Health condition details:
Diagnosis, Medication requirements, Risk factors for constipation or faecal incontinence, Presence of Autism or stoma
Diet and fluid management:
Instructions, Monitoring requirements
Bowel management:
Daily schedule, Stool appearance reference, Actions required, Supplies needed
Monitoring and recording:
Bowel chart usage, Effectiveness review, Shift reporting
Review timeline:
Scheduled review period, Next review date, Signs for immediate review
Emergency management:
Faecal incontinence, Chronic constipation, Urinary tract infection, Skin integrity risks, Autonomic dysreflexia
Context:
Clinical care document outlining individualized bowel management procedures, risk monitoring, and emergency responses for participants requiring high-intensity support.
Year:
2018
Region / City:
Milton Keynes
Theme:
Healthcare policy for spinal cord injury (SCI) care
Document type:
Policy
Organization:
Spinal Injuries Association
Author:
Carol Adcock, Debbie Green
Target audience:
Healthcare providers, clinical staff, NHS trusts
Review date:
January 2023
Approval date:
July 2018
Revision date:
January 2025
Year:
2023
Region / City:
New Zealand
Topic:
Bowel cancer screening, interval cancers, screening sensitivity
Document Type:
Report
Organization:
New Zealand Cancer Registry
Author:
Not specified
Target Audience:
Healthcare professionals, researchers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified